Loading organizations...
Loading organizations...
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2024 | Memo Therapeutics | $22.0M Series C | — | Kurma Partners, Adjuvant Capital, Fresenius Medical Care Ventures, Pureos Bioventures, Redalpine, Schroders Capital, Swisscanto Invest, Verve Ventures, Vesalius Biocapital, Thomas Harth |
| Nov 1, 2023 | Memo Therapeutics | $28.0M Series C | Veronica Gambillara Fonck | Adjuvant Capital, Kurma Partners, Pureos Bioventures, Fresenius Medical Care Ventures, Redalpine, Schroders Capital, Swisscanto Invest, Verve Ventures, Vesalius Biocapital |
| Feb 1, 2022 | Memo Therapeutics | $25.0M Series B | Swisscanto Invest, Swiss Federal Office of Public Health | Adjuvant Capital, Kurma Partners, Pureos Bioventures, Andreas Wüpper, Verve Ventures, Christian Schneider, Zürcher Kantonalbank |